
    
      Lu AA21004 is under codevelopment by Takeda Global Research & Development Center, Inc. and H.
      Lundbeck A/S for the treatment of MDD.

      This study will consist of a screening period within 10 days of the Baseline Visit followed
      by an 8-week double-blind treatment period and a one-week taper down period.
    
  